arbekacin has been researched along with Disease Models, Animal in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hasegawa, H; Izumikawa, K; Kaku, N; Kosai, K; Miyazaki, T; Morinaga, Y; Mukae, H; Takeda, K; Uno, N; Yanagihara, K | 1 |
| Hikida, M; Kawabata, T; Maebashi, K; Niida, M; Sakakibara, S; Takata, T | 1 |
| Morikawa, K; Nonaka, M; Torii, I; Yoshikawa, Y | 2 |
| Chow, JW; Donabedian, SM; Kak, V; Kariyama, R; Kumon, H; Zervos, MJ | 1 |
| Ishii, Y; Tanaka, A | 1 |
6 other study(ies) available for arbekacin and Disease Models, Animal
| Article | Year |
|---|---|
Efficacy and pharmacokinetics of ME1100, a novel optimized formulation of arbekacin for inhalation, compared with amikacin in a murine model of ventilator-associated pneumonia caused by Pseudomonas aeruginosa.
Topics: Administration, Inhalation; Amikacin; Animals; Anti-Bacterial Agents; Dibekacin; Disease Models, Animal; Drug Compounding; Lung; Mice; Microbial Sensitivity Tests; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections | 2017 |
[Combined effects of arbekacin with biapenem against in vitro and in vivo model of a mixture of MRSA and Pseudomonas aeruginosa].
Topics: Aminoglycosides; Animals; Anti-Infective Agents; Dibekacin; Disease Models, Animal; Drug Combinations; Drug Resistance, Bacterial; Drug Therapy, Combination; Male; Methicillin Resistance; Mice; Mice, Inbred ICR; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Staphylococcus aureus; Thienamycins | 2004 |
Synergistic effect of fosfomycin and arbekacin on a methicillin-resistant Staphylococcus aureus-induced biofilm in a rat model.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Biofilms; Dibekacin; Disease Models, Animal; Drug Synergism; Fosfomycin; Granuloma; Male; Methicillin Resistance; Microbial Sensitivity Tests; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus | 2005 |
Effect of arbekacin on a methicillin-resistant Staphylococcus aureus-induced biofilm in a rat model.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Biofilms; Dibekacin; Disease Models, Animal; Granuloma; Humans; Male; Methicillin Resistance; Microscopy, Electron, Scanning; Necrosis; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome | 2004 |
Efficacy of ampicillin plus arbekacin in experimental rabbit endocarditis caused by an Enterococcus faecalis strain with high-level gentamicin resistance.
Topics: Aminoglycosides; Ampicillin; Animals; Anti-Bacterial Agents; Dibekacin; Disease Models, Animal; Drug Resistance, Microbial; Drug Therapy, Combination; Endocarditis, Bacterial; Enterococcus faecalis; Gentamicins; Gram-Positive Bacterial Infections; Microbial Sensitivity Tests; Rabbits; Treatment Outcome | 2000 |
Mechanical properties of the femur after injection of calcium phosphate cement containing arbekacin sulfate and polylactic acid in a rat model of experimental osteoporosis.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Biocompatible Materials; Bone Cements; Calcium Phosphates; Dibekacin; Disease Models, Animal; Drug Delivery Systems; Female; Femur; Lactic Acid; Osteoporosis; Polyesters; Polymers; Rats; Rats, Sprague-Dawley; Stress, Mechanical | 2002 |